Microbiotica nabs $67M to push 2 microbiome therapies through clinicnews2022-03-07T16:22:33+00:00March 7th, 2022|FierceBiotech|
Astellas gets safety win for phase 3 menopause drug, setting up US, EU filingsnews2022-03-07T15:16:28+00:00March 7th, 2022|FierceBiotech|
AstraZeneca tacks on another $100M to wrap up over-budget R&D centernews2022-03-07T14:18:37+00:00March 7th, 2022|FierceBiotech|
Death in Alpine’s Keytruda combo trial triggers clinical hold, raises specter of earlier tragedynews2022-03-07T14:08:17+00:00March 7th, 2022|FierceBiotech|
SalubrisBio’s bispecific heart failure drug boosted by $32M cash injection news2022-03-07T13:16:30+00:00March 7th, 2022|FierceBiotech|
vTv CEO resigns 4 months into job after slashing workforce, refocusing pipelinenews2022-03-04T13:50:52+00:00March 4th, 2022|FierceBiotech|
Shionogi’s COVID-19 vaccine matches Pfizer’s Comirnaty in booster trialnews2022-03-04T13:40:12+00:00March 4th, 2022|FierceBiotech|
BeiGene’s hematology CMO resigns in wake of solid tumor switchnews2022-03-04T12:58:45+00:00March 4th, 2022|FierceBiotech|
Synairgen’s NIH-sponsored COVID-19 trial paused a day after SAB study nixed completelynews2022-03-03T18:37:00+00:00March 3rd, 2022|FierceBiotech|
Bristol Myers Squibb to consolidate R&D units in San Diego in new complexnews2022-03-03T16:27:50+00:00March 3rd, 2022|FierceBiotech|
